New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
Next Generation Sequencing-Enhanced Antibody Discovery
Using Reptor for NGS-enhanced antibody discoveryTraditional antibody discovery methods, such as hybridoma and phage display, as well as newer single cell screening methods, capture only a small portion of the adaptive immune response, and as a result isolate a small...
BCR Repertoire Sequencing: Error Correction
Sequencing errors: where do they come from?Immune repertoire sequencing (Rep-seq) allows us to deconvolute the population of antibody sequences that comprise an individual’s B-cell response. While antibody repertoire diversity is known to be vast, errors can cause a...
VHH Discovery By Serum Proteomic Analysis
Llama VHH discovery from serumCamelids, such as llamas and alpacas, naturally produce both conventional antibodies and heavy-chain only antibodies (HCAbs)(1). The antigen-binding domain of the HCAb, called the VHH or nanobody, is comprised of a single polypeptide...
Get In Touch